CAPN3 and neuromuscular disease caused by qualitative or quantitative defects of dysferlin: With the exception of countries such as Norway, Denmark and Finland, where the founder effect was determined, LGMD2A is the most frequent type of LGMD worldwide, followed either by dysferlinopathies in some areas or by sarcoglycanopthies in others (Fig. 1).